Introduction {#S1}
============

The increased availability of EHRs fostered by the HITECH Act has a great potential to serve as a rich, integrated source of phenotype information ([@B6]; [@B5]). Critical to this effort is computational phenotyping, which identifies patients with certain conditions of interest from EHR data ([@B7]). A list of computational phenotyping algorithms covering over fifty diseases ([@B19]) including RA ([@B13]; [@B18]) and T2DM are available at the PheKB, primarily developed through the eMERGE Network. The majority of the eMERGE phenotyping algorithms were developed to identify cases and controls of specific medical conditions for use in genome and phenome-wide association studies ([@B20]). However, developing research quality EHR-based computational phenotyping algorithms that categorize disease or traits in complete populations is not an easy task, as the primary purpose of EHR data is for healthcare delivery and reimbursement practices ([@B24]). Case/control EHR algorithms are powerful tools in research, however, the ability to characterize real-world clinical patient populations that are comprised of a mix of primary care patients (i.e., medical home), transient patients, and referral patients resulting in varying patterns of depth and detail in EMR data is more challenging. Thus, data fragmentation, or incomplete data due to patient movement across healthcare institutions, is an inherent limitation of using EHR data for research ([@B21]), and creates challenges in validating EHR-based phenotypes in populations ([@B14]). While extensive investigations on computational phenotyping have been performed to improve algorithm performance and portability ([@B11]; [@B12]; [@B14]; [@B24]; [@B23]), the impact of data fragmentation on computational phenotyping is under investigated. We identified only one study which evaluated the impact of data fragmentation on algorithm performance. Using data from two healthcare institutions, the study demonstrated that running a T2DM phenotyping algorithm, developed by researchers from Northwestern University, on data from a single institution missed almost one third of the T2DM cases ([@B25]).

Using the Mayo Biobank cohort, we assessed the impact of data fragmentation on two popular eMERGE phenotyping algorithms, RA and T2DM, as these two diseases differ greatly in prevalence. Specifically, the overall prevalence of RA is estimated at 0.5%([@B9]) while T2DM is a common disease affecting approximately 8.6% adults in the United States ([@B2]). Additionally, the RA algorithm is regression-based while the T2DM algorithm is rule-based.

Materials and Methods {#S2}
=====================

Data Sources {#S2.SS1}
------------

In this study, we used the Mayo Clinic Biobank cohort ([@B15]) with the following self-reported data collected at the time of consent into the Biobank: general health, self and first-degree relative family disease history, and demographic characteristics. The clinical data for the cohort can be retrieved from two sources: Mayo Clinic EHRs and the REP ([@B22]). The REP is a record linkage system which links and archives medical records from multiple healthcare providers in Minnesota and Wisconsin including Mayo Clinic since 2010 ([@B22]). All analyses were based on a subset of the Biobank cohort consisting of 45,183 patients who have at least one diagnosis code in Mayo Clinic EHRs and at least one diagnosis code in the REP during 2010 and 2017. We used diabetes family history from the Biobank self-reported data to run the T2DM phenotyping algorithm. All patients in the chosen Biobank cohort consented to have their EHR data used for research. This study was approved by the Institutional Review Board of Mayo Clinic.

Phenotyping Algorithms {#S2.SS2}
----------------------

The eMERGE RA algorithm was created using a machine-learning penalized logistic regression model trained on a screen-positive data set with at least one RA diagnosis code (inclusion cohort) ([Figure 1](#F1){ref-type="fig"}). Among the training set, the gold standard for model development was built up based on the 2010 American College of Rheumatology criteria for classification of RA ([@B1]). In the model, relative weights for features significantly associated with RA, including diagnosis of RA, SLE, PA, lab tests for rheumatoid factor, and total number of encounters (visits) per subject were assigned. Once the model was created, a threshold value based on a specificity of 97% was selected to identify cases. We used an updated version of the algorithm (the Harvard eMERGE RA Algorithm Document downloaded from <https://phekb.org/phenotype/rheumatoid-arthritis-ra>) which incorporates ICD 9 and 10 codes. Comparing to the previous version using only ICD 9 ([@B4]), the updated version achieved sensitivity, PPV, and overall area under the curve of 87, 95, and 95%, respectively, compared to 65, 90, and 95% previously. Controls were selected from persons without any RA diagnosis codes and without any exclusion codes.

![The eMERGE algorithm for identifying RA cases and controls. Adapted from [@B18].](fgene-11-00556-g001){#F1}

As stated above, the eMERGE T2DM algorithm^[1](#footnote1){ref-type="fn"}^ was developed by researchers from Northwestern University in 2012 ([@B10]). It is a rule-based algorithm based on diabetes related diagnosis, lab, and medication information, achieving 98 and 100% PPV for T2DM case and control identification, respectively. In addition to structured EHR data, in this study, we also extracted physician entered diagnoses from clinical notes of both Mayo and REP sources leveraging natural language processing (NLP) techniques. We updated the algorithm to incorporate ICD 10 codes which have been adopted in late 2015 in the United States ([@B8]). To collect more complete data, we also added medication extracted by NLP from clinical notes in both Mayo and REP sources. [Figure 2](#F2){ref-type="fig"} shows the flowchart of T2DM case phenotyping algorithm and [Figure 3](#F3){ref-type="fig"} shows the flowchart of T2DM control phenotyping algorithm.

![The eMERGE algorithm for identifying T2DM cases. Adapted from [@B17].](fgene-11-00556-g002){#F2}

![The eMERGE algorithm for identifying T2DM controls. Adapted from [@B17].](fgene-11-00556-g003){#F3}

Analysis {#S2.SS3}
--------

We assessed data fragmentation by evaluating the performance of the phenotyping algorithms in the cohort. To evaluate phenotyping errors caused by data fragmentation across health institutions, we used subjects identified from the combination of Mayo and REP data as the benchmark. To evaluate the performance of the phenotyping algorithms, we randomly selected 50 cases and 50 controls for each algorithm from the benchmark to perform manual review. We calculated sensitivity, specificity, PPV and FNR based on the number of TP, FP, TN, and FN against the benchmark ([@B25]). The impact of various data sources on quantitative change of features contributing to phenotyping was analyzed.

Results {#S3}
=======

[Table 1](#T1){ref-type="table"} shows the number of cases and controls identified by each data source as well as the combination of sources. Using both Mayo Clinic EHRs and REP data, we identified 620 RA cases (42,319 controls) and 5,215 T2DM cases (6,293 controls) to serve as our benchmark for the analyses. [Table 2](#T2){ref-type="table"} shows performance of RA and T2DM phenotyping algorithms in benchmark against chart reviewed gold standards. PPV of RA case was 90% compared to 95% in the updated version of the algorithm. PPVs of T2DM case and control were 82 and 100% compared to 98 and 100% in the publication ([@B10]).

###### 

Phenotyping results using various data sources.

  **Phenotyping algorithm**   **Case**   **Control**                             
  --------------------------- ---------- ------------- ------- -------- -------- --------
  Rheumatoid Arthritis        620        605           498     4,2319   42,398   43,070
  Type 2 diabetes mellitus    5,215      5,124         4,850   6,293    6,482    6,815

###### 

Performances of RA and T2DM phenotyping algorithms in benchmark (against chart reviewed gold standard).

  **Phenotyping algorithms**   **TPs**   **FPs**   **TNs**   **FNs**   **Sensitivity (TP/TP+FN), %**   **Specificity \[TN/(FP+TN)\], %**   **PPV \[TP/(TP+FP)\], %**   **FNR \[FN/(TP+FN)\], %**
  ---------------------------- --------- --------- --------- --------- ------------------------------- ----------------------------------- --------------------------- ---------------------------
  RA case                      45        5         49        1         97.8                            90.7                                90.0                        2.2
  RA control                   49        1         45        5         90.7                            97.8                                98.0                        9.3
  T2DM case                    41        9         50        0         1                               84.7                                82.0                        0
  T2DM control                 50        0         41        9         84.7                            1                                   1                           15.3

[Table 3](#T3){ref-type="table"} shows benchmark performance of RA and T2DM cases and controls using various data sources. Using Mayo only data, the RA phenotyping algorithm identified 43 FP RA case subjects, missed 165 FN RA case subjects (FNR, 26.6%), and identified 751 FP RA control subjects because of data fragmentation across healthcare institutions. The T2DM phenotyping algorithm identified 368 FP T2DM case subjects, missed 733 FN T2DM case subjects (FNR, 14%), identified 597 FP T2DM control subjects and missed 75 FN T2DM control subjects (FNR, 1.2%) because of data fragmentation across healthcare institutions. Fewer errors were resulted using REP only data, the RA phenotyping algorithm identified 17 FP RA case subjects, missed 32 FN RA case subjects (FNR, 5.2%), and identified 79 FP RA control subjects because of data fragmentation across healthcare institutions. The T2DM phenotyping algorithm identified 91 FP T2DM case subjects, missed 173 FN T2DM case subjects (FNR, 3.3%), identified 245 FP T2DM control subjects and missed 56 FN RA control subjects (FNR, 0.9%) because of data fragmentation across healthcare institutions.

###### 

Benchmark performance of RA and T2DM cases and controls using various data sources.

  **Phenotyping algorithm**   **Data source**   **TPs**    **FPs**   **TNs**   **FNs**   **Sensitivity (TP/TP+FN), %**   **Specificity \[TN/(FP+TN)\], %**   **PPV \[TP/(TP+FP)\], %**   **FNR \[FN/(TP+FN)\], %**   
  --------------------------- ----------------- ---------- --------- --------- --------- ------------------------------- ----------------------------------- --------------------------- --------------------------- ------
  RA                          Case              Mayo+REP   620       0         44,563    0                               100                                 100                         100                         0
                                                Mayo       455       43        44,520    165                             73.4                                99.9                        91.4                        26.6
                                                REP        588       17        44,546    32                              94.8                                99.9                        97.2                        5.2
                              Control           Mayo+REP   42,319    0         2,864     0                               100                                 100                         100                         0
                                                Mayo       42,319    751       2,113     0                               100                                 73.8                        98.3                        0
                                                REP        42,319    79        2,785     0                               100                                 100                         99.8                        0
  T2DM                        Case              Mayo+REP   5,215     0         39,968    0                               100                                 100                         100                         0
                                                Mayo       4,482     368       39,600    733                             86.0                                99.1                        92.4                        14.0
                                                REP        5,124     91        39,795    173                             96.7                                99.8                        98.3                        3.3
                              Control           Mayo+REP   6,293     0         38,890    0                               100                                 100                         100                         0
                                                Mayo       6,218     597       38,293    75                              98.8                                98.5                        91.2                        1.2
                                                REP        6,237     245       38,645    56                              99.1                                99.4                        96.2                        0.9

Further analysis showed that the 150 out of 165 RA false negative cases obtained from the Mayo only data source were in the Mayo Clinic inclusion cohort (positive-screening set; [Table 3](#T3){ref-type="table"}). Among the 32 RA false negative cases in REP data source, all were in the REP inclusion cohort. [Figure 4](#F4){ref-type="fig"} presents the RA probabilities of all benchmark cases (620) derived from Mayo Clinic, REP, and the combination of Mayo and REP data. Probability estimated from Mayo and REP data show multiple regression lines, reflecting heterogenicity among healthcare providers. The red line intercepts the cutoff of 0.632; probabilities above the red line indicate RA cases. [Figure 4](#F4){ref-type="fig"} shows that probabilities of the FN in Mayo or REP sources improved after combining Mayo data with REP data.

![Probability of all benchmark cases based on various data sources. The red line intercepts the cutoff of 0.632, probabilities above the red line are classified as RA cases.](fgene-11-00556-g004){#F4}

[Table 4](#T4){ref-type="table"} shows statistics of features associated with RA phenotyping in various data sources between 2010 and 2017, specifically the number of patients with RA, PA, and SLE diagnosis codes, laboratory tests for rheumatoid factor as well as total number of encounters for the Mayo Biobank cohort. The inclusion cohort increased to 2,127 using both Mayo and REP data, with an increase of 524 compared to Mayo and 69 compared to REP. 15 of the 524 was identified as an RA case in the combined Mayo and REP data. [Supplementary Figure S1](#FS1){ref-type="supplementary-material"} shows RA case probabilities of the false negative Mayo inclusion cohort (524 subjects) in the combination of Mayo and REP data, only several subjects had values close to the cutoff (0.632). [Supplementary Figure S2](#FS2){ref-type="supplementary-material"} shows RA case probabilities of the false negative REP inclusion cohort (69 subjects) in the combination of Mayo and REP data, no subject had value above the cutoff.

###### 

Statistics of features associated with RA case phenotyping in various data sources.

  **Data sources**   **\# of Cases meeting algorithm criteria**   **\# of patients with 1+ RA diagnosis codes (inclusion cohort)**   **\# of Patients with 1+ PA diagnosis codes**   **\# of patients with 1+ SLE diagnosis codes**   **\# of patients with 1+ Lab test for rheumatoid factor**   **Total encounter No. (for the Mayo Clinic Biobank cohort)**
  ------------------ -------------------------------------------- ------------------------------------------------------------------ ----------------------------------------------- ------------------------------------------------ ----------------------------------------------------------- --------------------------------------------------------------
  Mayo+REP           620                                          2,127                                                              83                                              68                                               1,293                                                       3,039,483
  Mayo               498                                          1,603                                                              52                                              53                                               907                                                         2,850,109
  REP                605                                          2,058                                                              79                                              64                                               1,254                                                       2,776,569

RA, rheumatoid arthritis; PA, psoriatic arthritis; SLE, systemic lupus erythematosus.

The flowcharts ([Figures 5](#F5){ref-type="fig"}, [6](#F6){ref-type="fig"}) show the comparison of each step of T2DM case and control phenotyping algorithms among various data sources, where the number denoting each step is from [Figures 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}, respectively. The detailed statistics are provided in [Supplementary Tables S1](#TS1){ref-type="supplementary-material"}, [S2](#TS2){ref-type="supplementary-material"}. Using only Mayo data, 1 of the 733 FN T2DM cases have been falsely identified as a control, and 1 benchmark case was falsely identified as a control among the 597 FP T2DM controls. [Table 5](#T5){ref-type="table"} shows factors that contribute to FP and FN RA case subjects. There are 751 FP controls from Mayo and 79 FP controls from REP due to incomplete diagnosis codes in each institution. [Table 6](#T6){ref-type="table"} shows factors that contribute to FP and FN T2DM case subjects. [Table 7](#T7){ref-type="table"} shows factors that contribute to FP and FN T2DM control subjects.

###### 

Missing information for FN and FP RA case subjects.

  **Error type**   **Data sources**   **Total No. of subjects**   **No. of subjects with missing information**                
  ---------------- ------------------ --------------------------- ---------------------------------------------- --- --- ---- --------
  FN               Mayo               165                         15                                             1   0   14   17,674
                   REP                32                          0                                              0   0   0    2,654
  FP               Mayo               43                          0                                              0   0   0    2,112
                   REP                17                          0                                              0   0   0    1,083

###### 

Missing information for FN and FP T2DM case subjects.

  **Error type**   **Data source**   **Total No. of subjects**   **No. of subjects with missing information**                         
  ---------------- ----------------- --------------------------- ---------------------------------------------- ---- ---- ----- ----- ---
  FN               Mayo              733                         0                                              22   36   248   532   0
                   REP               173                         0                                              46   3    25    8     0
  FP               Mayo              368                         246                                            17   90   39    25    0
                   REP               82                          0                                              12   13   7     0     0

###### 

Missing information for FN and FP T2DM control subjects.

  **Error type**   **Data source**   **Total No. of subjects**   **No. of subjects with missing information**                          
  ---------------- ----------------- --------------------------- ---------------------------------------------- ---- ----- ----- ----- ---
  FN               Mayo              75                          10                                             65   0     0     0     0
                   REP               56                          11                                             45   0     0     0     0
  FP               Mayo              597                         0                                              0    122   166   362   0
                   REP               245                         0                                              0    4     236   5     0

![Quantitative comparison of each step in T2DM case phenotyping among various data sources. The number of each step corresponds to [Figure 2](#F2){ref-type="fig"}, bold numbers are derived from the combination of Mayo of REP data.](fgene-11-00556-g005){#F5}

![Quantitative comparison of each step in T2DM control phenotyping among various data sources. The number of each step corresponds to [Figure 3](#F3){ref-type="fig"}, bold numbers are derived from the combination of Mayo of REP data.](fgene-11-00556-g006){#F6}

Discussion {#S4}
==========

Electronic health records have been an asset for studies whose goal is to define cases and controls with high accuracy. However, leveraging EHRs for population studies is more challenging. Inherent data issues and bias (e.g., data fragmentation and referral bias) of EHRs may result in inaccurate and biased phenotyping results. RA and T2DM phenotyping algorithms to define cases and controls have been well studied by researchers with high performances within separate institutions ([@B4]; [@B25]). These two diseases have also been fertile ground for secondary use of EHRs in combination with DNA samples ([@B27]; [@B12]; [@B3]). Therefore, it is worthwhile to investigate and evaluate the impact of data fragmentation on completeness and validity of algorithm results. To the best of our knowledge, this study is the first to evaluate the impact of data fragmentation on RA phenotyping algorithm. When assessing the impact of data fragmentation on T2DM, the FNR is 14% in our current study in comparison to 33% reported previously ([@B25]) as we leveraged NLP to extract more complete diagnosis and medication information from clinical notes. Our performance metrics of the benchmark against chart reviewed gold standard are slightly inferior to those metrics published previously, which is consistent with other studies, primarily due to the heterogenicity of healthcare systems impacting algorithm portability ([@B16]).

As a regression-based algorithm, the sensitivity of the RA phenotyping depends on the comprehensiveness of the data, partially due to the complex relationships between autoimmune disorders. Systemic lupus erythematosus and PA both interfere with RA diagnosis. Total encounter numbers also exert adverse effects on RA case identification. Though RA diagnosis and positive RA lab results were assigned with relatively high positive weights, SLE, PA, and all encounter numbers were assigned with negative weights in the algorithm. In our study, 150 out of 165 FN cases in Mayo were already in the Mayo inclusion cohort and all FN cases in REP were in the REP inclusion cohort.

As a medical record-linkage system, REP captures more comprehensive diagnosis codes than Mayo EHRs resulting in fewer benchmark phenotyping errors. Meanwhile, not all information in Mayo EHRs is included in REP. For example, REP misses the diagnosis information coming from the Problem List in Mayo EHRs. Using Mayo only data, the RA phenotyping algorithm missed 165 FN RA case subjects (FNR = 26.6%) and the T2DM phenotyping algorithm missed 733 FN T2DM case subjects (FNR = 14%). All FN and FP cases, FN and FP controls defined using only Mayo data or only REP data were masked or falsely identified due to missing or insufficient information.

Although we investigated only two phenotyping algorithms in this study, the findings would also have implications for other research that relies on case and control identification using EMERGE algorithms. Considering the potential impact of data fragmentation on data quality for genomic research, clinical researchers should always keep this caveat in mind when employing a phenotyping algorithm for such studies. Ideally, adding data from a medical record linkage system or a comprehensive claims data source (such as the Centers for Medicare and Medicaid Services) can capture and reuse clinical information more efficiently. In addition, unstructured data extracted using NLP techniques could help to decrease data fragmentation because unstructured clinical notes in EHRs often record patients' history of past diseases which may have been originally diagnosed and treated in other health institutions. Finally, besides the data fragmentation issue, temporal issues could also result in incomplete phenotyping results. Researchers have conducted a related study on T2DM ([@B26]), and we also investigated the dependence of the eMERGE RA algorithm on both RA and electronic health record (EHR) duration in another manuscript (Journal of the American Medical Informatics Association, in press).

The limitation of the study is that we didn't have fully-annotated gold standards. Because of the high PPV seen in previous studies ([@B10]; [@B4]), (95% for RA case, 98% and 100% for T2DM case and control), we set the benchmark for evaluation to be the phenotyping results based on the combination of data from both Mayo and REP, and only manually reviewed 50 cases and 50 controls for each algorithm to validate. In addition, the study would have been more generalizable if data from multiple sites had been independently collected.

Conclusion {#S5}
==========

In this study, we demonstrated that various data sources may result in different phenotyping results through two case studies. We also identified underlying reasons for variation in the algorithm performance. The completeness and validity of phenotypic and exposure information derived from EHRs are the foundations for precision medicine and patient care. As more genomic research makes use of EHR-derived phenotypes, it is important to understand that data fragmentation may significantly affect algorithm performance.
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